Jazz Pharmaceuticals plc JAZZ
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
4/9
Piotroski F — financial health
1.63
Altman Z″ — distress risk · grey
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $4.3B | -$356.1M | — | $1.3B | $4.3B |
| 2024 | $4.1B | $560.1M | — | $1.4B | $4.1B |
| 2023 | $3.8B | $414.8M | — | $1.1B | $3.7B |
| 2022 | $3.7B | -$224.1M | — | $1.2B | $3.1B |
| 2021 | $3.1B | -$329.7M | — | $750.9M | $4.0B |
| 2020 | $2.4B | $238.6M | — | $884.6M | $3.7B |
Why these scores methodology →
Piotroski F-score: 4/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 1.63 (grey)
- Working capital / assets 0.165
- Retained earnings / assets 0.055
- EBIT / assets -0.037
- Equity / liabilities 0.588
Source: SEC EDGAR filings · CIK 0001232524 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.